Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity
by Zacks Equity Research
Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $202.02, moving -0.34% from the previous trading session.
United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF
by Zacks Equity Research
United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.
Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?
by Zacks Equity Research
Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.
Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment
by Zacks Equity Research
Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.
Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention
by Zacks Equity Research
The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.
Lilly (LLY) Up 11.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021
Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod
by Zacks Equity Research
Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
by Zacks Equity Research
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Lilly's (LLY) Fifth Tirzepatide Study Meets All Key Endpoints
by Zacks Equity Research
Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.
New Strong Sell Stocks for May 19th
by Zacks Equity Research
ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
New Strong Sell Stocks for May 13th
by Zacks Equity Research
PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021
Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
New Strong Sell Stocks for May 11th
by Zacks Equity Research
PFPT, KLR, GDDY, LLY, and FUV have been added to the Zacks Rank #5 (Strong Sell) List on May 11, 2021
Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.
Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi
by Zacks Equity Research
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.